natgillin/translations-raw huggingface dataset:
The full EPAR for Enbrel can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Cjelovito Europsko javno izvješće o ocjeni dokumentacije o lijeku (EPAR) za lijek Enbrel nalazi se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This compared with around a quarter of the patients receiving placebo. 
To je uspoređeno s otprilike četvrtinom bolesnika koji su primali placebo.
For adults, the usual recommended dose is 25 mg twice a week or 50 mg once a week. 
U slučaju odraslih osoba, uobičajena preporučena doza iznosi 25 mg dva puta na tjedan ili 50 mg jednom na tjedan.
Treatment with 50 mg twice a week can also be used during the first 12 weeks of treatment for plaque psoriasis. 
Terapija dozom od 50 mg dva puta na tjedan može se također koristiti tijekom prvih 12 tjedana liječenja plak psorijaze.
The patient or carer can give the injection if they have been trained appropriately. 
Bolesnik ili skrbnik može ubrizgati injekciju ako su prošli ispravnu obuku.
The European Commission granted a marketing authorisation valid throughout the European Union for Enbrel on 3 February 2000. 
Europska komisija izdala je odobrenje za stavljanje u promet koje za lijek Enbrel na snazi u Europskoj uniji od 03. veljače 2000.
By blocking TNF, etanercept reduces the inflammation and other symptoms of the diseases. 
Inhibirajući TNF, etanercept smanjuje upalu i druge simptome bolesti.
What measures are being taken to ensure the safe and effective use of Enbrel? 
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Enbrel?
Etanercept is produced by a method known as ‘recombinant DNA technology': it is made by cells that have received a gene (DNA) that makes them able to produce etanercept. 
Etanercept se proizvodi metodom poznatom pod nazivom „tehnologija rekombinatne DNK“: proizvodi se od stanica koje prime gen (DNK) koji im omogućuje proizvodnju etanercepta.
Other information about Enbrel 
Ostale informacije o lijeku Enbrel
One of these studies examined Enbrel's effects as an add-on to methotrexate in 89 patients. 
Jedno od ovih ispitivanja istražilo je djelovanje lijeka Enbrel kao dodatka metotreksatu u 89 bolesnika.
Enbrel must not be used in patients who have or are at risk of sepsis (when bacteria and toxins circulate in the blood and start to damage the organs), or in patients with infections. 
Enbrel se ne smije koristiti u bolesnika koji imaju ili su izloženi riziku sepse (kada bakterija i toksini cirkuliraju u krvi i počinju oštećivati organe) ili u bolesnika s infekcijama.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Enbrel. 
Objašnjava kako je Odbor za lijekove za humanu uporabu (CHMP) ocijenio lijek da bi donio svoje mišljenje u korist davanja odobrenja za stavljanje lijeka u promet i svoje preporuke o uvjetima za primjenu lijeka Enbrel.
The fifth study compared the effectiveness of Enbrel, methotrexate and a combination of both in 686 patients. 
Peto je ispitivanje usporedilo djelotvornost lijeka Enbrel, metotreksata i kombinaciju oboje u 686 bolesnika.
This is a summary of the European public assessment report (EPAR) for Enbrel. 
Ovo je sažetak Europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Enbrel.
• certain forms of juvenile idiopathic arthritis (a rare childhood disease causing inflammation of many joints) in the following groups: 
• određenih oblika juvenilnog idiopatskog artritisa (rijetke dječje bolesti koja uzrokuje upalu mnogih zglobova) u sljedećih grupa:
The most common side effects with Enbrel (seen in more than 1 patient in 10) are injection site reactions (including bleeding, bruising, redness, itching, pain and swelling) and infections (including colds, and lung, bladder and skin infections). 
Najčešće nuspojave lijeka Enbrel (kod više od 1 na 10 bolesnika) su reakcije u mjestu injekcije (uključujući krvarenje, podljeve, crvenilo, svrbljenje, bol i oticanje) i infekcije (uključujući prehlade i infekcije pluća, mjehura i kože).
A risk management plan has been developed to ensure that Enbrel is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Enbrel.
For all other diseases studied, Enbrel produced a greater improvement in symptoms than placebo after three to four months. 
Za sva ostala ispitivanja bolesti, terapija lijekom Enbrel rezultirala je većim poboljšanjem u simptomima od placeba nakon tri do četiri mjeseca.
In the study of patients who had not taken methotrexate before, those receiving 25 mg Enbrel twice a week had less joint damage than those taking methotrexate alone after 12 and 24 months. 
U ispitivanju bolesnika koji nisu uzeli metotreksat prije, bolesnici koji su primali 25 mg Enbrela dvaputa tjedno imali su manje ozljeda zglobova od bolesnika koji su uzimali samo metotreksat nakon 12 ili 24 mjeseca.
In the fourth study, Enbrel was compared with methotrexate in 632 patients who had not taken methotrexate before. 
U četvrtom ispitivanju, Enbrel je uspoređen s metotreksatom u 632 bolesnika koji nisu prethodno uzimali metotreksat.
Enbrel can also be used in patients with severe rheumatoid arthritis who have not taken methotrexate before; 
Enbrel se može također koristiti u bolesnika s ozbiljnim reumatoidnim artritisom koji ranije nisu uzimali metotreksat;
• psoriatic arthritis in adults who have not responded adequately to other treatments; 
• psorijatičnog artritisa u odraslih osoba koje nisu primjereno odgovorile na druga liječenja;
Enbrel has been studied in five main studies in rheumatoid arthritis, involving about 2,200 patients and lasting from three months to two years. 
Enbrel se ispitivao u pet glavnih ispitivanja u reumatoidnom artritisu, koje je obuhvatilo otprilike 2.200 bolesnika i trajalo je od tri mjeseca do dvije godine.
Enbrel is used in patients who have not responded to or cannot receive other treatments for this disease. 
Enbrel se koristi u bolesnika koji nisu odgovorili na druga liječenja ili ih ne mogu primiti za ovu bolest.
Overall, in the studies of rheumatoid arthritis, about two-thirds of the patients receiving Enbrel had a reduction in symptoms of 20% or more after three months. 
Ukupno gledano u ispitivanjima reumatoidnog artritisa, otprilike dvije trećine bolesnika koji su primali Enbrel imalo je smanjenje simptoma od 20% ili više nakon tri mjeseca.
For more information about treatment with Enbrel, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Više informacija o terapiji lijekom Enbrel pročitajte u uputi o lijeku (također dio EPAR-a), ili se obratite svom liječniku ili ljekarniku.
The active substance in Enbrel, etanercept, is a protein that has been designed to block the activity of a chemical messenger in the body called tumour necrosis factor (TNF). 
Djelatna tvar lijeka Enbrel, etanercept, je protein koji je dizajniran za inhibiranje aktivnosti kemijskog glasnika u tijelu naziva čimbenik tumorske nekroze (TNF).
The company that makes Enbrel will provide educational material for doctors expected to prescribe the product (to teach patients how to use the pre-filled pen correctly) and for patients (so they can recognise any serious side effects, and know when to seek urgent attention from their doctor). 
Proizvođač lijeka Enbrel dostavit će edukacijski materijal liječnicima za koje se očekuje da će propisivati lijek (kako bi se bolesnici obučili za ispravnu primjenu napunjenog aplikatora) i bolesnicima (tako da mogu prepoznati svaku ozbiljnu nuspojavu te znati kada je potrebno potražiti hitan savjet liječnika).
What is the risk associated with Enbrel? 
Koji su rizici povezani s lijekom Enbrel?
The studies in children with polyarticular juvenile idiopathic arthritis and plaque psoriasis were followed up with long term studies to assess the safety of long term treatment in children. 
Ispitivanja u djece oboljele od poliartikularnog juvenilnog idiopatskog artritisa i plak psoriaze popračena su dugoročnim ispitivanjima kako bi se ocijenila sigurnost dugoročnog liječenja u djece.
Enbrel treatment should be started and supervised by a specialised doctor who has experience in the diagnosis and treatment of the diseases that Enbrel is used to treat. 
Liječenje Enbrelom treba započeti i nadzirati liječnik specijalist s iskustvom u dijagnostici i liječenju bolesti za koje je Enbrel indiciran.
Patients developing a serious infection should stop Enbrel treatment. 
Bolesnici u kojih se razvije ozbiljna infekcija trebaju prestati uzimati terapiju lijekom Enbrel.
Enbrel is an anti inflammatory medicine. 
Enbrel je protuupalni lijek.
The CHMP decided that Enbrel's benefits are greater than its risks and recommended that it be given marketing authorisation. 
CHMP odlučio je da koristi od lijeka Enbrel nadmašuju s njim povezane rizike te je preporučio izdavanje odobrenja za stavljanje lijeka u promet.
• plaque psoriasis (a disease causing red, scaly patches on the skin) in adults with moderate to severe disease and in patients from the age of six years with long-term severe disease;. 
• plak psorijaze (bolesti koja uzrokuje crvenu, suhu, ljuskavu kožu) u odraslih osoba s umjerenom do ozbiljnom bolesti i u bolesnika u dobi od šest godina s dugoročnom ozbiljnom bolesti.
The long term safety studies found that Enbrel could be used in polyarticular juvenile idiopathic arthritis in children from the age of two years and plaque psoriasis from the age of six years. 
Ispitivanja dugoročne sigurne primjene utvrdila su da se Enbrel može koristiti za liječenje poliartikularnog juvenilnog idiopatskog artritisa u djece u dobi od dvije godine i plak psorijaze u dobi od šest godina.
• Severe non-radiographic axial spondyloarthritis (a chronic inflammatory disease of the spine) when there are objective signs of inflammation but no abnormalities seen on x-ray. 
• ozbiljanog neradiološkog aksijalnog spondiloartritisa (kronične upalne bolesti kralježnice) kada postoje objektivni znakovi upale, no nema uočenih abnormalnosti na rendgenu.
• moderate to severe rheumatoid arthritis (an immune system disease causing inflammation of the joints) in adults (aged 18 years or over). 
• umjerenog do teškog reumatoidnog artritisa (bolesti imunosnog sustava koja uzrokuje upalu zglobova) u odraslih osoba (u dobi od 18 godina ili starijih).
Three studies compared Enbrel with placebo (a dummy treatment) in patients who had taken arthritis medicines in the past. 
Tri su ispitivanja usporedila Enbrel s placebom (lažnim liječenjem) u bolesnika koji su prethodno uzimali lijekove za liječenje artritisa.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Enbrel, including the appropriate precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Enbrel nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Why has Enbrel been approved? 
Zašto je lijek Enbrel odobren?
Enbrel is used with methotrexate (a medicine that acts on the immune system) in adults with moderate or severe disease who have not responded adequately to other treatments, or on its own if methotrexate is not suitable for the patient. 
Enbrel se koristi u kombinaciji s metotreksatom (lijekom koji djeluje na imunosni sustav) u odraslih osoba s umjerenom ili teškom bolesti, a koji nisu odgovarajuće odgovorili na druga liječenja ili kao monoterapija ako metotreksat nije primjeren za liječenje bolesnika.
What is Enbrel? 
Što je Enbrel?
Enbrel was also compared with placebo in 51 children with polyarticular juvenile idiopathic arthritis, 205 adults with psoriatic arthritis, 357 adults with ankylosing spondylitis, 1,263 adults and 211 children with plaque psoriasis, as well as in 225 patients with non-radiographic axial spondyloarthritis. 
Enbrel je također uspoređen s placebom u 51 djeteta s poliartikularnim juvenilim idiopatskim artritisom, 205 odraslih osoba s psorijatskim artritisom, 357 odraslih osoba s ankiloznim spondilitisom,
It is available as vials containing a powder that is made up into a solution for injection, and as prefilled syringes and pens containing a solution for injection. 
Dostupan je kao bočice koje sadrže prašak za pripremu otopine za injekciju, te kao napunjene injekcije i aplikatori koji sadrže otopinu za injekciju.
Enbrel is a medicine that contains the active substance etanercept. 
Enbrel je lijek koji sadrži djelatnu tvar etanercept.
In the fifth study, Enbrel on its own or in combination with methotrexate was more effective than methotrexate alone. 
U petom ispitivanju, monoterapija Enbrelom ili Enbrel u kombinaciji s metotreksatom bili su učinkoviti od monoterapije metotreksatom.
This messenger is found at high levels in patients with the diseases that Enbrel is used to treat. 
Ovaj je glasnik prisutan u velikim koncentracijama u bolesnicima s bolestima za čije je liječenje Enbrel indiciran.
For more information, see the package leaflet. 
Za više informacija, pročitajte uputu o lijeku.
What is Enbrel used for? 
Za što se Enbrel koristi?
patients aged two to 17 years who have polyarthritis (rheumatoid factor positive or negative) and extended oligoarthritis and have not responded adequately to or cannot take methotrexate; 
bolesnika u dobi od 17 godina koji imaju poliartritis (pozitivan ili negativan reumatoidni faktor) i produljen oligoartritis te nisu primjereno odgovorili na metotreksat ili ga ne mogu uzimati;
What benefit has Enbrel shown during the studies? 
Koje su koristi lijeka Enbrel utvrđene u ispitivanjima?
• severe ankylosing spondylitis (a disease causing inflammation of the joints of the spine) in adults who have not responded adequately to other treatments; 
• ozbiljnog aksijalnog spondiloartritisa (bolesti koja uzrokuje upalu zglobova kralježnice) u odraslih osoba koje ne odgovaraju primjereno na druga liječenja;
Patients who take Enbrel must be given the special alert card that summarises important safety information about the medicine. 
Bolesnicima koji se liječe Enbrelom treba dati karticu s upozorenjima za bolesnika koja sadži informacije o lijeku.
Enbrel is given by injection under the skin. 
Enbrel se primjenjuje supkutanom injekcijom.
How is Enbrel used? 
Kako se Enbrel koristi?
adolescents aged 12 to 17 years who have psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) and have not responded adequately to or cannot take methotrexate; adolescents aged 12 to 17 years who have enthesitis-related arthritis and have not responded adequately to or cannot take standard treatment. 
adolescenata u dobi od 12 do 17 godina koji imaju psorijatični artritis (bolest koja uzrokuje crvenu, suhu, ljuskavu kožu i upalu zglobova) te nisu primjereno odgovorili na metotreksat ili ga ne mogu uzimati;
For the full list of all side effects reported with Enbrel, see the package leaflet. 
Potpuni popis nuspojava zabilježenih pri primjeni lijeka Enbrel, potražite u uputi o lijeku.
How has Enbrel been studied? 
Kako se Enbrel ispitivao?
How does Enbrel work? 
Kako djeluje Enbrel?
ATCvet code: QC03DA01. 
ATCvet kod: QC03DA01.
Wash hands after use. 
Po korištenju treba oprati ruke.
Food increases the bioavailability from 80 % to 90 %. 
Hrana povećava bioraspoloživost na 80 % do 90 %.
Do not use in animals used for, or intended for use in breeding. 
Ne koristiti u životinja koje se koriste za, ili su namijenjene uzgoju.
Detailed information on this veterinary medicinal product is available on the website of the European Medicines Agency http://www.ema.europa.eu/. 
Detaljne informacije o ovom veterinarsko - medicinskom proizvodu su dostupne na web stranici Europske Medicinske Agencije (EMA) http://www.ema.europa.eu/.
If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon. 
Ukoliko primijetite ikakve ozbiljne nuspojave ili nuspojave koji nisu spomenute u ovoj uputi molimo da o tome obavijestite vašeg veterinara.
5 to 10 kg 10 to 15 kg 15 to 20 kg 20 to 30 kg 30 to 40 kg 40 to 50 kg 50 to 60 kg 
5 do 10 kg 10 do 15 kg 15 do 20 kg 20 do 30 kg 30 do 40 kg 40 do 50 kg 50 do 60 kg
The tablet can either be mixed with a small amount of food offered prior to the main meal, or administered directly into the mouth after feeding. 
Tableta se može umiješati u manju količinu hrane koja se daje prije glavnog dijela obroka ili se može dati izravno u usta nakon hranjenja.
Très le Bois 22600 Loudéac France 
22600 Loudéac
Although the precise mechanism of action is not yet clearly defined, aldosterone promotes myocardial fibrosis, myocardial and vascular remodelling and endothelial dysfunction. 
Iako točan mehanizam djelovanja još nije jasno definiran, aldosteron pospješuje miokardijalnu fibrozu, miokardijalnu i vaskularnu prilagodbu i disfunkciju endotela.
Pharmacotherapeutic group: Aldosterone antagonist. 
Farmakoterapijska grupa: Antagonisti aldosterona.
Use within 2 months after first opening the bottle. 
Upotrijebiti u roku od 2 mjeseca po prvom otvaranju bočice.
Spironolactone may cause both induction and inhibition of cytochrome P450 enzymes and could therefore affect the metabolism of other drugs utilizing these metabolic pathways. 
Spironolakton može uzrokovati i indukciju i inhibiciju citokrom P450 enzima te na taj način djelovati na metabolizam drugih lijekova koji koriste te metaboličke putove.
Date of first authorisation: 20 June 2007 Date of last renewal: 22 May 2012 
Datum zadnjeg produljenja odobrenja: 22.5.2012.
After oral administration of spironolactone to dogs, it was demonstrated that the three metabolites achieved levels from 32 % to 49 % of the administered dose. 
Nakon peroralnog davanja spironolaktona psima pokazalo se da tri metabolita postižu razinu od 32 % do 49 % od primijenjene doze.
Do not use during pregnancy or lactation. 
Ne koristiti tijekom graviditeta i laktacije.
Following oral administration of 2 to 4 mg/kg, absorption increases linearly over the range. 
Nakon peroralnog davanja od 2 do 4 mg / kg, absorpcija se povećava linearno.
Spironolactone. 
Spironolakton.
Polyamide/aluminium/polyvinyl chloride//aluminium blisters containing 10 tablets. 
Poliamid / aluminij / polivinil klorid / aluminijski blisteri koji sadržavaju 10 tableta.
Spironolactone is mainly excreted via its metabolites. 
Spironolakton se uglavnom izlučuje putem svojih metabolita.
Artificial beef flavour Compressible sugar Magnesium stearate 
Umjetna aroma govedine Stlačivi šećer Magnezijev stearat
Sodium laurilsulfate Microcrystalline cellulose Povidone 
Natrijev lauril sulfat Mikrokristalična celuloza Povidon
30 tablets 180 tablets 
180 tableta
As the therapeutic index for digoxin is very narrow, it is advisable to monitor closely dogs receiving both digoxin and spironolactone. 
Kako je terapeutski indeks digoksina vrlo uzak preporuča se pažljivo praćenje pasa koji primaju digoksin zajedno sa spironolaktonom.
For a full list of excipients, see section 6.1. 
Popis pomoćnih tvari vidi u odjeljku 6.1
Do not use in conjunction with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) in dogs with renal insufficiency (kidney impairment/dysfunction). 
Ne koristiti zajedno s nesteroidnim protuupalnim lijekovima (NSPUL) u pasa s bubrežnom insuficijencijom (umanjenom funkcijom / disfunkcijom bubrega).
Dogs treated concomitantly with spironolactone and NSAIDs should be correctly hydrated. 
Psi koji se istodobno liječe sa spironolaktonom i NSULP trebaju biti pravilno rehidrirani.
This is thought to be due to activation of feedback mechanisms without adverse clinical consequence. 
To se pripisuje aktivaciji mehanizma povratne sprege bez štetnih kliničkih posljedica.
Spironolactone is a natriuretic drug (historically described as a soft diuretic). 
Spironolakton je natrijuretički lijek (poznat je kao blagi diuretik).
In experimental models in dogs, it was shown that long term therapy with an aldosterone antagonist prevents progressive left ventricle dysfunction and attenuates left ventricle remodelling in dogs with chronic heart failure. 
U eksperimentalnim modelima u pasa, dokazano je da dugotrajnije liječenje antagonistima aldosterona sprječava progresivnu disfunkciju i slabi preoblikovanje lijeve klijetke u pasa s kroničnim zatajenjem srca.
Cardboard box containing 3 or 18 blisters of 10 tablets. 
Kartonska kutija s 3 ili 18 blistera po 10 tableta.
May cause skin sensitisation: people with known hypersensitivity to spironolactone should avoid contact with the veterinary medicinal product. 
Proizvod može uzrokovati kožne reakcije: osobe preosjetljive na spironolakton trebaju izbjegavati kontakt s ovim veterinarsko - medicinskim proizvodom.
In a clinical study investigating the survival time in dogs with congestive heart failure, there was a 65% reduction in the relative risk of mortality at 15 months in dogs treated with spironolactone in combination with standard therapy compared to dogs treated with standard therapy alone. 
U kliničkom ispitivanju vremena preživljavanja pasa s kongestivnim zatajenjem srca rezultati su pokazali smanjenje rizika smrtnosti za 65 % kroz 15 mjeseci u pasa liječenih sipronolaktonom u kombinaciji sa standardnom terapijom u odnosu na pse liječene isključivo standardnom terapijom (smrtnost je klasificirana kao smrt ili eutanazija zbog zatajenja srca).
Do not use during pregnancy and lactation, laboratory studies in species (rat, mouse, rabbit and monkey) have shown evidence of developmental toxicity. 
Laboratorijska istraživanja na različitim životinjskim vrstama (štakorima, miševima, kunićima i majmunima) pokazale su pojavu razvojne toksičnosti.
6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products 
6.6 Posebne mjere predostrožnosti za odlaganje neupotrjebljenog veterinarsko - medicinskog proizvoda ili otpadnih materijala dobivenih primjenom tih proizvoda
Tablet. 
Tablete.
Furosemide and pimobendan have been used together with Spironolactone Ceva in dogs with heart failure without any clinical evidence of adverse reactions. 
Furosemid i pimobendan korišteni su zajedno sa Prilactonom u pasa sa zatajenjem srca, bez kliničkih manifestacija nuspojava.
Lactose monohydrate Cellulose, microcrystalline Crospovidone Povidone K30 
Laktoza monohidrat Mikrokristalična celuloza Krospovidon Povidon K30
1 to 2.5 kg 
1 do 2.5 kg
It is therefore recommended to induce vomiting, gastric lavage (depending on risk assessment) and monitor electrolytes. 
Stoga se preporučuje poticanje povraćanja, ispiranje želuca (ovisno o procjeni rizika) te praćenje elektrolita.
Do not use after the expiry date which is stated on the carton and blister label after EXP. 
Ne koristiti nakon isteka roka trajanja označenog na kutiji i bočici nakon EXP.
The mean volumes of distribution (Vss) of 7α-thiomethyl-spironolactone and canrenone are approximately 153 litres and 177 litres, respectively. 
Prosječne količine distribucije (Vss) 7α - tiometil - spironolaktona i kanrenona su oko 153 litre, odnosno 177 litara.
Beef flavouring Mannitol 
Aroma govedine Manitol
2.5 to 5 kg 
2.5 do 5 kg
After oral administration of radiolabelled spironolactone to the dog, 70 % of the dose is recovered in faeces and 20 % in the urine. 
Nakon peroralnog davanja radiološki označenog spironolaktona psima 70 % primljene doze izlučeno je izmetom, a 20 % mokraćom.
Spironolactone is rapidly and completely metabolised by the liver into its active metabolites, 7αthiomethyl-spironolactone and canrenone, which are the primary metabolites in the dog. 
Spirinolakton se brzo i u potpunosti metabolizira u jetri u svoje aktivne metabolite, 7α - tiometilspironolakton i kanrenon, koji su primarni metaboliti u pasa.
In case of an accidental massive ingestion by a dog, there is no specific antidote or treatment. 
U pasa, kod slučajnog gutanja veće količine lijeka, ne postoji specifičan lijek ili liječenje.